[8, 12, 19] However, the complexity of the GR signaling pathway and interactions with the tumor microenvironment and immune modulation contribute to an incomplete understanding of a therapeutic role for GR antagonism in advanced ER-negative breast cancer treatment. This evidence concerns the gene NR3C1 and neoplasm.